Age-related near vision loss has long been treated as an inevitable annoyance of getting older, a slow erosion of clarity ...

The FDA just approved a first-of-its kind medication, meaning there is now a “complete, non-invasive option” for people with this common type of visual impairment.

The US Food and Drug Administration has approved a landmark eye drop that uses a combined dose of medication to restore age-related near-sightedness, without the need for surgery, for a longer ...

Presbyopia is defined as age-related loss of near vision that affects nearly everyone over age 45. The FDA has approved Vizz, an aceclidine ophthalmic solution 1.44%, making it the first and only ...

A new eye drop, Vizz, was recently FDA approved and is helping people regain near vision without glasses. Originally used for glaucoma, the drops are now repurposed for presbyopia (age-related ...

Viatris Inc. (NASDAQ:VTRS) and Opus Genetics, Inc. (NASDAQ:IRD) revealed topline results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for ...

Please provide your email address to receive an email when new articles are posted on . LNZ100 improved near vision by at least two lines in 91% of participants. LNZ100 also improved distance vision.

The FDA has approved a first-of-its-kind eye drop that addresses a common vision condition. The once-daily drops will treat an age-related condition that causes blurry near vision. The drops are ...

A discussion of his situation led to the selection of the enVista Envy IOL. One month postoperatively, the patient achieved 20/20–2 vision bilaterally, with a small amount of myopia in the right eye ...